Ratings Thermo Fisher Scientific Inc. Sao Paulo

Equities

TMOS34

BRTMOSBDR007

Market Closed - Sao Paulo Other stock markets 12:30:26 08/06/2024 am IST			5-day change	1st Jan Change
64.28 ^BRL	+1.40%		+4.13%	+19.79%

05/06	Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing	MT
03/06	Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With an expected P/E ratio at 36.49 and 31.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	+19.79%	222B	-
DANAHER CORPORATION	+13.72%	195B	B-
INTUITIVE SURGICAL, INC.	+23.79%	148B	B-
BOSTON SCIENTIFIC CORPORATION	+33.39%	113B	A-
SIEMENS HEALTHINEERS AG	+4.75%	66.45B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.59%	53.11B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.03B	B+
AGILENT TECHNOLOGIES, INC.	-4.35%	38.8B	A
GE HEALTHCARE TECHNOLOGIES INC.	-1.27%	34.85B	-
RESMED, INC.	+22.61%	30.98B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes